According to the latest report by IMARC Group, titled “Women’s Health Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” offers a comprehensive analysis of the industry, which comprises insights on the global women’s health diagnostics market share. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The global women’s health diagnostics market size reached US$ 21.62 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 35.7 Billion by 2027, exhibiting at a CAGR of 8.10% during 2022-2027.
Women’s health diagnostics focus on treating and identifying various psychosocial, physical, and biological conditions of female patients. For instance, they help detect ovarian and breast cancer, gynecology disorder, hormone therapy, sexual health, osteoporosis, sexually transmitted infections (STIs), menopause, and benign conditions affecting the female body function. They include a series of laboratory tests, tools, and procedures, including ultrasound, chemotherapy, magnetic resonance imaging (MRI), image-guided breast biopsy, cordocentesis, or umbilical cord sampling, computed tomography (CT), endoscopic ultrasound (EUS), nipple discharge exam, nonstress tests (NST), pelvic floor strength tests, and post-void residual measurement (PVR). Owing to these properties, women’s health diagnostic testing solutions find extensive applications in diagnostic and imaging centers, hospitals, home care, and clinics across the globe.
Downoad a PDF Sample for more detailed market insights: https://www.imarcgroup.com/womens-health-diagnostics-market/requestsample
Women’s Health Diagnostics Market Trends and Drivers:
The market is primarily driven by the increasing prevalence of infectious diseases, such as urinary tract infections (UTIs), human immunodeficiency virus (HIV), breast cancer, and tuberculosis, which impact the well-being of women. In addition, the growing health consciousness and rising awareness regarding the advantages of early diagnosis are contributing to the market growth.
Moreover, several research studies concluded that women are more likely to experience psychiatric disorders, including anxiety, and depression, during hormonal changes, which represents another major growth-inducing factor. Besides this, the introduction of hybrid imaging instruments with enhanced accuracy to diagnose cancer and the development of a genomics-based diagnostic test for early identification of women susceptible to pregnancy complications and preterm birth are propelling the market growth.
Along with this, governments of various countries are taking the initiative to provide free health checkups to pregnant women and distribute free self-testing kits, which are providing a thrust to the market growth. Furthermore, the rising infertility rate, aging women population, and increasing consumption of alcohol and drugs are some of the other factors creating a positive market outlook across the globe.
Note: We are in the process of updating our reports. If you want to receive the latest research data covering the time period from 2023 to 2028, along with industry trends, market size, and competitive analysis, click on the request sample report. The team would be able to deliver the latest version of the report in a quick turnaround time.
Global Women’s Health Diagnostics Market 2022-2027 Analysis and Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Women’s Health Diagnostics Companies:
Abbott Laboratories, Becton Dickinson and Company, bioMérieux SA, Cardinal Health Inc., Cook Group Incorporated, F. Hoffmann-La Roche AG, General Electric Company, Hologic Inc., Koninklijke Philips N.V., Perkinelmer Inc., Quest Diagnostics Inc., Siemens AG and Thermo Fisher Scientific Inc.
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/womens-health-diagnostics-market
The report has segmented the market on the basis of region, type, application and end user.
Breakup by Type:
- Diagnostic Devices
- Biopsy Device
- Imaging and Monitoring Devices
- Accessories and Consumables
- Diagnostic Tests
- Breast Cancer Testing
- PAP Smear and HPV Test
- Pregnancy Testing and Ovulation Testing
Breakup by Application:
- Breast Cancer
- Infectious Disease Testing
- Osteoporosis Testing
- Pregnancy and Fertility Testing
- Sexually Transmitted Disease Testing
Breakup by End User:
- Hospital and Diagnostics Centers
- Home Care
Breakup by Region:
- North America
- United States
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Key highlights of the report:
- Market Performance (2016-2021)
- Market Outlook (2022- 2027)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Services Private Limited.
134 N 4th St.
Brooklyn, NY 11249, USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800